2022 International Congress » Parkinson’s Disease: Clinical Trials

A double-blind randomized clinical trial to evaluate the effects of Candesartan for Cognitive and Neuropsychiatric Impairment in Parkinson’s Disease

J. Kulisevsky, S. Martinez-Horta, A. Campolongo, B. Pascual-Sedano, J. Marin-Lahoz, H. Bejr-Kasem, A. Puig-Davi, J. Pagonabarraga, J. Rodriguez-Antiguedad (Barcelona, Spain)

A facilitated self-management toolkit for people with Parkinson’s disease: A feasibility study of ‘Live Well with Parkinson’s

M. Armstrong, T. Rookes, A. Schrag, K. Walters (London, United Kingdom)

A motor-cognitive intervention impacts daily-living gait and activity in Parkinson’s disease fallers differently than a motor intervention: analysis using a machine learning approach

K. Cohavi, S. Del Din, E. Gazit, E. Pelosin, L. Avanzino, N. Nieuwboer, B. Bloem, A. Cereatti, U. Croce, L. Rochester, N. Giladi, J. Hausdorff, A. Mirelman (Tel Aviv Yafo, Israel)

A Phase 1b study to test the safety, pharmacokinetics, and pharmacodynamics of a novel inflammasome inhibitor in early-stage Parkinson’s disease: Rationale and study design

G. D'Urso, A. Thomann, J. Anzures-Cabrera, B. Zinnhardt, B. Ricci, M. Marchesi, V. Machado, E. Mracsko, N. Pavese, K. Marek, K. Brockmann, T. Simuni, N. Milani Muelhardt, G. Pagano (Basel, Switzerland)

A Pilot Feasibility Study of Medium Chain Triglyceride Nutritional Ketosis and Parkinson’s Disease

A. Choi, M. Delgado, K. Chen, S. Chung, A. Courville, S. Turner, S. Yang, K. Airaghi, I. Dustin, P. Mcgurrin, M. Hallett, D. Ehrlich (Sun City, USA)

A randomized clinical trial (RCT) to evaluate the effects of safinamide on apathetic non-demented Parkinson’s disease patients

J. Kulisevsky, S. Martinez-Horta, A. Campolongo, B. Pascual-Sedano, J. Marin-Lahoz, H. Bejr-Kasem, A. Horta-Barba, A. Puig-Davi, J. Pagonabarraga, I. Aracil-Bolaños, J. Rodriguez-Antiguedad (Barcelona, Spain)

A randomized controlled trial comparing the efficacy and safety of pyridostigmine versus midodrine for the treatment of orthostatic hypotension in Parkinson’s disease patients

C. Limwatthana (Bangkok, Thailand)

A Week in the Life with Parkinson’s Disease: A Holistic Overview from Four Digital Technologies

E. Hartman, K. Dinesh, M. Pawlik, S. Jensen-Roberts, E. Waddell, T. Myers, J. Soto, E. Nnadika, P. Yang, G. Sharma, M. Islam, A. Abdelkader, W. Rahman, V. Antony, E. Hoque, G. Zhang, Y. Liu, D. Katabi, R. Wilson, K. Lizarraga, C. Tarolli, R. Schneider, E. Dorsey, J. Adams (Rochester, USA)

ADOPTION Study: Status update of a Randomised, Open-Label Exploratory Trial of Opicapone in Parkinson’s Disease

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, R. Costa, D. Magalhães, J. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Amantadine Is Effective Long-term in Parkinson’s Disease

S. Park, BS. Jeon (Daejeon, Republic of Korea)

Apathy and Volume of Tissue Activated (VTA) following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Cohort

T. Stiep, A. Ramirez-Zamora, J. Wong, A. Tröster, R. Jain, L. Chen, M. Malek, M. Okun (Gainesville, USA)

Apomorphine Sublingual Film for OFF Episodes in Parkinson’s Disease: Incremental Motor Improvement Observed with Increasing Doses

S. Isaacson, I. Zhang, E. Pappert, A. Bowling (Boca Raton, USA)

Apomorphine Sublingual Film Titrated at Home in Patients With Parkinson’s Disease and OFF Episodes: Results From an Open-Label, Randomized, Crossover Study

J. Kassubek, F. Stocchi, E. Balaguer, S. Isaacson, I. Zhang, A. Bowling, S. Wu, E. Pappert (Ulm, Germany)

Apomorphine Sublingual Film Versus Subcutaneous Apomorphine in the Treatment of OFF Episodes in Parkinson’s Disease: Results From an Assessment of Patient Satisfaction

J. Schwarz, C. Carroll, G. Ebersbach, J. Kulisevsky, A. Tessitore, I. Zhang, A. Bowling, S. Wu, E. Pappert, A. Thach (Oberbayern, Germany)

Awake versus Asleep Deep Brain Stimulation Lead Placement: Real-World Outcomes with Directional DBS Systems

J. Vesper, G. Deuschl, L. Chen, R. Jain (Düsseldorf, Germany)

Binaural acoustic stimulation reduces tremor severity in patients suffering from Parkinson’s disease

A. Calvano, L. Timmermann, C. Oehrn, I. Weber (Marburg, Germany)

Case reports of first experiences worldwide with novel continuous oral levodopa dental pump in Parkinson’s Disease Patients

D. Mcintyre, O. Terwindt, L. Pavelka, G. Schilling, A. Znati, L. Skhiri, M. Gantenbein, E. Heller, A. Heller, J. Kennedy, J. Harmon, C. Kamp, M. Torti, CW. Olanow, R. Krueger (Strassen, Luxembourg)

Challenges in Outcome Measure Selection in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease

C. Gonzalez-Robles, M. Bartlett, M. Burnell, R. Chapman, R. Chaudhuri, C. Clarke, R. Ellis-Doyle, M. Hu, B. Huxford, A. Jha, M. Lawton, G. Mills, A. Noyce, P. Piccini, L. Rochester, J. Rudiger, C. Siu, D. van Wamelen, C. Williams-Gray, ML. Zeissler, H. Zetterberg, C. Carroll, T. Foltynie, R. Weil, A. Schrag (London, United Kingdom)

Climb up! Head up! Climbing improves posture in Parkinson’s disease. A randomised controlled trial.

A. Langer, D. Roth, A. Santer, A. Flotz, J. Gruber, L. Wizany, S. Hasenauer, R. Pokan, P. Dabnichki, M. Treven, S. Zimmel, M. Schmoeger, U. Willinger, L. Gassner, W. Maetzler, H. Zach (Vienna, Austria)

CLINICAL AND GENEOLOGICAL FEATURES OF PARKINSON’S DISEASE

S. Kuranbaeva, S. Kalandarova, A. Umarov, G. Goyibova (Tashkent, Uzbekistan)

COMPARISON OF CERVICAL, OCULAR AND MASSETER VESTIBULAR EVOKED MYOGENIC POTENTIALS IN PARKINSON PATIENTS ACCORDING TO CLINICAL SUBGROUPS

G. Sahbaz, R. Inan, B. Barut (Istanbul, Turkey)

Concomitant Medication Use and Levodopa Equivalent Daily Dose Requirements After Foslevodopa/foscarbidopa Initiation

D. Santos Garcia, L. Bergmann, B. Bergmans, F. Bergquist, S. Criswell, V. Fung, J. Jia, P. Kukreja, N. Pavasia, W. Robieson, Z. Zhang, D. Standaert (A Coruña, Spain)

Cycling Deep Brain Stimulation for Parkinson’s Disease

C. França, A. Bertholo, A. Pelicheck, I. Paraguay, J. Reis, D. Barros, J. Yamamoto, A. Coelho, R. Otani, M. Reuter, R. Carra, T. Guimarães, M. Teixeira, E. Barbosa, R. Cury (São Paulo, Brazil)

Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612

A. Espay, A. Ellenbogen, T. Gurevich, R. Case, L. Adar, T. Yardeni, L. Salin (Cincinnati, USA)

Design of a prodromal screening study for subtypes in Parkinson’s Disease

E. Schaeffer (Kiel, Germany)

Design of the Remote Optimization Adjustment and Measurement for Deep Brain Stimulation (ROAM-DBS) Randomized Controlled Trial Using Decentralized Patient Monitoring

T. Tomlinson, A. Gharabaghi, S. Groppa, L. Luo, H. Lu, M. Feldman, C. Luca, V. Marshall, A. Merola, L. Muñoz-Delgado, A. Schnitzler, L. Verhagen, B. Walter, C. Wu, S. Zauber, L. Zhang, B. Cheeran (Plano, USA)

Designing a multi-arm multi-stage trial for Parkinson’s

M-L. Zeissler, M. Burnell, T. Barber, Y. Ben-Shlomo, R. Chapman, C. Clarke, C. Counsell, M. Edwards, R. Ellis-Doyle, C. Gonzales-Robles, A. Jewell, G. Mills, J. Rudiger, D. Salathiel, S. Whipps, A. Whone, T. Foltynie, C. Carroll, R. Barker, J. Carpenter (Plymouth, United Kingdom)

Developing infrastructure for a multi-arm multi-stage trial in Parkinson’s

M-L. Zeissler, J. Allison, D. Athauda, S. Bartolomeu Pires, G. Baxendale, K. Bhatia, D. Breen, R. Chapman, H. Collins, R. Croucher, R. Ellis-Doyle, C. Gonzales-Robles, F. Hudson, R. Khengar, P. Korlipara, C. Lambert, G. Mills, A. Morgan, H. Morris, J. Rudiger, M. Silverdale, S. Wonnacott, A. Yarnall, T. Foltynie, C. Carroll, S. Mullin (Plymouth, United Kingdom)

Duration of continuous “Good On” intervals and number of motor fluctuations after treatment with IPX203 vs immediate-release carbidopa-levodopa in Parkinson’s disease patients with motor fluctuations.

R. Hauser, H. Fernandez, J. Aldred, C. Singer, H. Shill, S. Factor, H. Visser, R. D'Souza (Tampa, USA)

Dynamical modulations of low frequency deep brain stimulation on axial symptoms in Parkinson’s disease

Y. Thenaisie, L. Comeliau, C. Varescon, L. Asboth, M. Castro, J. Bally, G. Courtine, J. Bloch, E. Martin Moraud (Lausanne, Switzerland)

Early Morning Dystonia in Parkinson’s Patients Receiving Opicapone versus Entacapone: a Post-Hoc Analysis of BIPARK-I

F. Stocchi, J. Ferreira, W. Poewe, O. Rascol, A. Antonini, J-F. Rocha (Rome, Italy)

Effect of exercise on motor symptoms, non-motor symptoms and dopamine transporter imaging in Parkinson Disease

J. Morley, J. Dubroff, G. Cheng, B. Taylor, S. Wood, J. Duda (Philadelphia, USA)

Effect of freezing of gait and antiparkinsonian medication on joint kinematics and kinetics in gait in patients with Parkinson’s disease

T. Shida, D. Campos, C. Oliveira, R. Treza, S. Hondo, E. Los Angeles, C. Bernardo, L. Oliveira, M. Carvalho, D. Coelho (São Bernardo Campo, Brazil)

Effect of freezing of gait on the neural activity during the cognitive-motor conflict in step initiation in individuals with Parkinson’s disease: a case study

L. de Oliveira, C. de Oliveira, P. Bazán, C. Bernardo, E. Los Angeles, M. Carvalho, J. Sato, A. de Lima-Pardini, D. Coelhodaniel, A. Baptista (Diadema, Brazil)

Effect of KW-6356, a novel adenosine A2A receptor antagonist/inverse agonist, on motor and non-motor symptoms in Parkinson’s disease patients as an adjunct to levodopa therapy: Results of Phase 2b study

T. Maeda, K. Sugiyama, K. Yamada, M. Nishi, N. Hattori (Iwate, Japan)

Effect of lower limb vs. abdominal compression on mobility in orthostatic hypotension – a single-blinded, randomized, controlled, cross-over study in Parkinson’s disease

S. Paschen, C. Hansen, J. Welzel, J. Albrecht, A. Atresaei, K. Aminian, KE. Zeuner, R. Romijnders, E. Warmerdam, PP. Urban, D. Berg, W. Maetzler (Kiel, Germany)

Effect of perception of vertical position on forward flexion posture in patients with Parkinson’s disease: A multicenter, observational study (interim report)

M. Shiraishi, K. Mikami, H. Kamo, T. Kamo, T. Tsunemi, Y. Okuma, K. Fujimoto, Y. Yokota, S. Nogawa, T. Osada, M. Seki, H. Nagayama, T. Hatano, H. Nakajima, K. Suzuki, T. Yamamoto, Y. Yamano, N. Hattori, M. Ijima (Kawasaki, Japan)

Effects of Parkinson’s disease and freezing of gait on the kinematic and kinetic gait parameters

D. Campos, T. Shida, C. Oliveira, R. Treza, S. Hondo, E. Los Angeles, C. Bernardo, L. Oliveira, M. Carvalho, D. Coelho (São Bernardo Campos, Brazil)

Efficacy of Apomorphine Sublingual Film Versus Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

F. Stocchi, O. Rascol, W. Poewe, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Rome, Italy)

Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial

HJ. Chang, J. Park, S. Oh, CW. Shin, JW. Cho, JY. Lee (Seoul, Republic of Korea)

Exploratory analysis of the effect of delayed-start prasinezumab on motor sign progression measured with the Roche PD Mobile Application v2: PASADENA Phase II Parts 1 and 2

K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, M. Scelsi, L. Essioux, A. Monnet, B. van Lier, H. Svoboda, T. Kustermann, W. Zago, T. Nikolcheva, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

Exploratory delayed-start analysis of PASADENA evaluating the efficacy of prasinezumab on motor progression and motor complications in early-stage Parkinson’s disease

G. Pagano, S. Zanigni, A. Monnet, K. Taylor, A. Hahn, T. Simuni, K. Marek, R. Postuma, N. Pavese, F. Stocchi, H. Svoboda, P. Fontoura, R. Doody, G. Kerchner, A. Bonni, T. Nikolcheva (Basel, Switzerland)

Feasibility of Sensor-Based Music Feedback In Patients With PD

S. Mainka, G. Ebersbach (Beelitz-Heilstaetten, Germany)

Frequency dependent interindividual variability of the deep brain stimulation effect on upper-limb bradykinesia

P. Dorin, D. Brogle, S. Hägele-Link, M. Krüger, G. Kägi, F. Brugger (St. Gallen, Switzerland)

Funding and Sustainability Challenges in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease

C. Gonzalez-Robles, J. Ahmed, C. Bale, R. Chapman, S. Clegg, E. Deeson, R. Ellis-Doyle, V. Greaves, J. Handley, E. Henderson, K. Matthews, S. Medd-Phillips, L. Miller, G. Mills, J. Rudiger, ML. Zeissler, C. Carroll, T. Foltynie, S. Gandhi, J. Duffen (London, United Kingdom)

Gait Characteristics from Daily Life Increase Ability to Predict Future Falls in People with Parkinson’s Disease

V. Shah, J. Mcnames, G. Harker, P. Carlson-Kuhta, J. Nutt, M. El Gohary, K. Sowalsky,, M. Mancini, F. Horak (Portland, USA)

Gut dysbiosis in patients with dementia with Lewy bodies

H. Nishiwaki, M. Ito, T. Hamaguchi, K. Kashihara, T. Maeda, Y. Tsuboi, M. Katsuno, M. Hirayama, K. Ohno (Nagoya, Japan)

Home-based transcranial static magnetic field stimulation of the motor cortex for treating levodopa-induced dyskinesias in Parkinson’s disease

M. Dileone, C. Ammann, V. Catanzaro, C. Pagge, R. Piredda, MHG. Monje, I. Navalpotro-Gómez, A. Bergareche, MC. Rodriguez-Oroz, L. Vela, F. Alonso-Frech, MJ. Catalán-Alonso, JA. Molina, N. López-Ariztegui, A. Oliviero, JA. Obeso, G. Foffani (Móstoles, Spain)

Identifying meaningful symptoms and impacts of disease for patients with early Parkinson’s disease

J. Mammen, R. Speck, R. Dorsey, M. Müller, P. Yang, S. Jensen-Roberts, M. Kostrzebski, J. Cosman, J. Hellsten, J. Crawford, G. Stebbins, J. Cedarbaum, T. Simuni, T. Dam, K. Ward Barowicz, D. Stephenson, J. Adams (Providence, USA)

IgG to neurotensin in blood of Parkinson’s disease patients

Z. Muruzheva, M. Absalyamova (Saint-Petersburg, Russian Federation)

IkT-148009 as a potential disease-modifying therapy in PD

M. Werner, S. Karuppagounder, R. Rush, T. Kelly, T. Dawson, V. Dawson (Atlanta, USA)

Impact of foslevodopa/foscarbidopa on key clinical and patient-reported outcomes in patients with aPD: Responder analysis of two Phase 3 clinical trials

M. Soileau, J. Aldred, A. Antonini, C. Carroll, V. Fung, T. Henriksen, R. Pahwa, D. Santos Garcia, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, A. Spiegel, M. Facheris, J. Zamudio, P. Kukreja, KR. Chaudhuri (Georgetown, USA)

Impact of istradefylline on the adjustment of levodopa dose escalation in Parkinson’s disease: Results of the ISTRA ADJUST PD randomized, controlled study

T. Hatano, O. Kano, R. Sengoku, N. Yanagisawa, H. Nagayama (Tokyo, Japan)

Importance of lifestyle advice for participants in studies of early Parkinson’s disease

F. Fuchs, I. Tödt, A. Rogge, J. Naumann, D. Berg, E. Schäffer (Kiel, Germany)

Improving the design of clinical trials in early-stage Parkinson’s disease by using the estimand framework

J. Anzures-Cabrera, A. Monnet, G. Pagano (Welwyn Garden City, United Kingdom)

Impulse Control Disorders Following Bilateral Subthalamic Deep Brain Stimulation for Parkinson’s Disease: The INTREPID Randomized Controlled Trial

T. Stiep, A. Tröster, A. Ramirez-Zamora, R. Jain, L. Chen, M. Okun (Gainesville, USA)

IncobotulinumtoxinA to treat sialorrhea in Parkinson’s disease: a real-life study

B. Bergmans, N. Winter, V. Schotte, N. Sys, E. van Massenhove, H. Couckuyt, M. van Zandijcke (Bruges & Ghent, Belgium)

Interventions to Improve Gait in Parkinson’s Disease: A Systematic Review of Randomised Controlled Trials and Network Meta-Analysis

V. Hvingelby, A. Glud, JC. Sørensen, Y. Tai, AS. Andersen, VE. Johnsen, E. Moro, N. Pavese (Aarhus N, Denmark)

Investigating the use of DAT-SPECT as an enrichment biomarker to determine eligibility for the phase 2 clinical trial PASADENA

T. Kustermann, S. Holiga, S. Zanigni, H. Svoboda, T. Nikolcheva, G. Pagano, K. Taylor (Basel, Switzerland)

Involving people with lived experience of Parkinson’s in trial design: the EJS ACT-PD initiative

M-L. Zeissler, N. Bakshi, M. Bartlett, A. Batla, D. Byrom, R. Chapman, E. Deeson, R. Ellis-Doyle, C. Gonzales-Robles, A. Jewell, H. Matthews, L. Miller, G. Mills, L. Mooney, A. Morgan, J. Rudiger, D. Salathiel, P. Scurfield, C. Siu, S. Whipps, S. Wonnacott, T. Foltynie, C. Carroll, K. Mcfarthing (Plymouth, United Kingdom)

IPX203 dose conversion from immediate-release carbidopa-levodopa, in Parkinson’s disease patients with motor fluctuations.

R. Hauser, A. Espay, W. Ondo, B. Safirstein, H. Moore, R. Kumar, G. Banisadr, S. Fisher (Tampa, USA)

Liraglutide once daily versus placebo in Parkinson’s disease: a randomized, double-blind, placebo-controlled trial

T. Wu, C. Bresee, J. Wertheimer, E. Hogg, C. Malatt, E. Tan, H. Pomeroy, G. Obialisi, M. Tagliati (Los Angeles, USA)

Long-Term Neuropsychological Outcomes of Deep Brain Stimulation in Early-Stage Parkinson’s Disease

M. Hacker, M. Tramontana, J. Meystedt, M. Turchan, K. Harper, B. Eoff, R. Fan, F. Ye, T. Davis, P. Konrad, D. Charles (Nashville, USA)

Long-term safety of continuous levodopa/carbidopa infusion with ND0612: Data from patients who continued past one year in the BeyoND study

S. Isaacson, N. Giladi, F. Stocchi, L. Salin, N. Vostokova, W. Poewe (Boca Raton, USA)

Longitudinal brain perfusion changes correlated with UPDRS Total in a Phase I mesenchymal stem cell trial for Parkinson’s disease

M. Schiess, J. Suescun, C. Adams, E. Tharp, K. Block, M. Doursout, T. Ellmore (Houston, USA)

Longitudinal clinical and biomarkers characteristics of non-manifest LRRK2 G2019S carriers: The PPMI cohort

T. Simuni, K. Merchant, M. Brumm, C. Caspell-Garcia, H. Cho, C. Coffey, L. Chahine, A. Siderowf, C. Tanner, K. Marek, P. Investigators (Chicago, USA)

Longitudinal evaluation of hypomimia in individuals with Parkinson’s disease using a video analytics tool

P. Yang, M. Islam, A. Abdelkader, W. Rahman, M. Pawlik, S. Jensen-Roberts, E. Waddell, T. Myers, J. Soto, E. Hartman, E. Nnadika, R. Wilson, K. Lizarraga, C. Tarolli, R. Schneider, E. Dorsey, J. Adams, E. Hoque (Rochester, USA)

Low-dose lithium therapy associated with increased PBMC Nurr1 and SOD1 expression in Parkinson’s disease: a pilot study.

T. Guttuso, JR., R. Shepherd, M. Tamano, M. Ramanathan, V. Frerichs, L. Frick (Williamsville, USA)

LRRK2 Inhibition by BIIB122: Trial designs for two efficacy and safety studies in Parkinson’s disease patients with and without LRRK2 mutations (Lighthouse and Luma)

J. Shirvan, D. Jennings, P. Wang, R. Maciuca, S. Sahu, F. Sedarati, A. Kay, K. Fraser, S. Huntwork-Rodriguez, M. Yang, M. Levee, P. Chin, T. Dam (Cambridge, USA)

Marker Progression and Sample Sizes Estimates for Trials in Prodromal Parkinson’s Disease: A Multicenter Study

S. Joza, M. Hu, KY. Jung, D. Kunz, P. Dusek, D. Arnaldi, B. Högl, L. Ferini-Strambi, M. Terzaghi, F. Sixel-Döring, M. Puligheddu, F. Provini, S. Lewis, J. Liu, J. Bušková, A. Nicoletti, Y. Dauvilliers, C. Bassetti, M. Lawton, HJ. Kim, JS. Sunwoo, F. Bes, K. Sonka, P. Mattioli, A. Stefani, A. Ibrahim, G. Fiamingo, B. Mollenhauer, C. Trenkwalder, M. Figorilli, P. Cortelli, L. Baldelli, K. Ehgoetz Martens, Y. Li, E. Cicero, L. Guiraud, C. Schaefer, A. Pelletier, R. Postuma (Montreal, Canada)

Measuring what matters in Parkinson’s disease – validating real-world digital mobility outcomes for widespread adoption

A. Yarnall, C. Schlenstedt, P. Ginis, H. Hildesheim, A. Mirelman, J. Hausdorff, A. Nieuwboer, H. Gassner, L. Alcock, P. Brown, H. Hunter, I. Neatrour, L. Sutcliffe, J. Winkler, J. Klucken, J. Kudelka, M. Gordon, C. Becker, W. Maetzler, L. Rochester (Newcastle, United Kingdom)

Month 24 results of a virtual longitudinal, observational study of Parkinson’s disease: The AT-HOME PD cohort

M. Zafar, J. Soto, E. Baloga, L. Omberg, E. Macklin, P. Snyder, K. Amodeo, T. Meyers, S. Duquette, C. Stevens, K. Lizzaraga, E. Nnadika, A. Sarkar, C. Tarolli, J. Adams, C. Lungu, J. Gottesman, B. Valdovinos, E. Dorsey, L. Mangravite, T. Simuni, M. Schwarzchild, R. Schneider (Rochester, USA)

Multicentric prospective study of subthalamic deep brain stimulation 1-year impact on speech in Parkinson’s disease

T. Ollivier (Lille, France)

Neuroprotective trial design methodology for Parkinson’s: a scoping review

E. King, M-L. Zeissler, P. Sharpe, T. Boey, F. O'Brian, D. Chapman, G. Rafaloff, K. Raphael, H. Venkatesh, C. Carroll (Plymouth, United Kingdom)

NONINVASIVE BRAINSTEM MODULATION FOR THE TREATMENT OF NONMOTOR SYMPTOMS IN PARKINSON’S DISEASE: A RANDOMIZED CONTROLLED TRIAL AND OPEN LABEL EXTENSION STUDY

K. Ade (Durham, USA)

OCEAN Study in Parkinson’s Disease: Status Update of a Randomised Double-Blind Placebo-Controlled Trial of Opicapone

K. Chaudhuri, P. Odin, J. Ferreira, A. Antonini, O. Rascol, M. Kurtis, A. Storch, K. Bannister, R. Costa, D. Magalhães, J-F. Rocha, P. Soares-da-Silva (London, United Kingdom)

Open-Label, Single-Arm, Exploratory Trial of Opicapone: Status Update of the OASIS (OPICAPONE IN SLEEP DISORDER) Study

R. Costa, J. Ferreira, D. Magalhães, J-F. Rocha, P. Soares-da-Silva (Coronado, Portugal)

Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson´s Disease: An Open-label Prospective Study

D. Santos García, G. Fernández Pajarín, J. Oropesa Ruíz, F. Escamilla Sevilla, R. Rahim Lopez, G. Muñoz Enríquez (A Coruña, Spain)

Optimizing patient-centric clinical outcome assessments for use in Parkinson’s disease clinical trials: Critical Path for Parkinson’s multistakeholder initiative

R. Speck, D. Trundell, J. Cedarbaum, M. Campbell, P. Chin, S. Crawford, T. Dam, D. Dexter, A. Goldfine, K. Klapper, C. Kopil, S. Lee, K. Marek, H. Matthews, T. Mestre, T. Morel, M. Minchik, M. Müller, K. Schroeder, T. Simuni, G. Stebbins, C. Yan, ML. Zeissler, D. Stephenson (Tucson, USA)

P2B001 in the management of untreated PD. Results from a randomized, double-blind, double-dummy controlled trial

C. Olanow, K. Kieburtz, P. Litman, H. Friedman, S. Oren (Sarasota, USA)

Parkinson`s disease in Pandemic Covid

S. Galbineanu, A. Ailene (Brasov, Romania)

Patient Advisory Boards: A Model for Patient Engagement in Parkinson’s Disease Comparative Effectiveness Research

K. Schroeder, C. Gallagher, M. Armstrong, M. Carnie, C. Evers, J. Fleisher, B. Kluger, J. Lamb, S. Seshadri, L. Wilson, M. Feeney, P. Davies (New York, USA)

Performance of oral diadochokinesis in Parkinson’s Disease motor subtypes

V. Dos Santos, R. Rothe-Neves,, A. Bressanelli, I. Klein, M. Olchik (Porto Alegre, Brazil)

Perturbation-based balance training in individuals with Parkinson’s disease and freezing of gait

DB. Coelho, C. Ribeiro Souza, J. ávila Oliveira, L. Rezende, P. Takazono, C. Silva-Batista, L. Teixeira (São Bernardo Campo, Brazil)

Progress of the UK Cholinesterase inhibitor to prevent falls in Parkinson’s disease (CHIEF-PD) trial

A. Bamford, S. Neumann, J. Taylor, G. Young, S. Emmett, W. Hollingworth, A. Whone, D. Steeds, C. Metcalfe, Y. Ben-Shlomo, E. Henderson (Bristol, United Kingdom)

Prospective, Multicenter, International Registry of Deep Brain Stimulation for Essential Tremor

G. Deuschl, R. Schuurman, G. Loret, N. Kovacs, M. Blázquez Estrada, F. Clement, J. Il Lee, L. Chen, R. Jain (Kiel, Germany)

Prospective, Multicenter, Real-World Outcomes Study with Directional Deep Brain Stimulation Systems in the Treatment of Parkinson’s Disease

M. Okun, K. Foote, T. Zesiewicz, Y. Bezchlibnyk, A. Papanastassiou, J. Ramirez-Castaneda, J. Carlson, J. Aldred, V. Krishna, A. Merola, C. Luca, J. Jagid, J. Durphy, L. Verhagen-Metman, S. Sani, S. Ojemann, D. Kern, D. Weintraub, R. Ramdhani, A. Siadati, B. Sundaram, C. Zhao, D. Martinez, M. Siddiqui, S. Tatter, J. Wang, R. Jain (Gainesville, USA)

Qualification of Digital Endpoints of Function in Healthy Volunteers for Use in a Decentralized Natural History Study in Genetic Parkinson’s Disease (PD)

S. Sankaranarayanan, C. Tomkins-Lane, D. Singamsetty, G. Yahalom, N. France, M. Maurer, C. Barlow (South San Francisco, USA)

Quality of Life and Motor Outcomes for Parkinson’s Disease Patients 12 Months After Deep Brain Stimulation in China

Y. Zhang, L. Chen, B. Sun, X. Wang, J. Wang, J. Wang, J. Woods, K. Stromberg, H. Shang (Chengdu, China)

Quality of life and patient reported outcomes with subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 BeyoND study

W. Poewe, F. Stocchi, L. Adar, T. Yardeni, A. Espay (Innsbruck, Austria)

Rapid onset of good ON time and improvement in motor-state stability in aPD patients after treatment with continuous subcutaneous foslevodopa/foscarbidopa

R. Pahwa, M. Soileau, D. Standaert, V. Fung, T. Kimber, I. Malaty, A. Merola, A. Epstein, C. Yan, A. Alobaidi, A. Shewale, N. Fisseha, A. Jeong, M. Facheris, P. Kukreja, J. Zamudio, J. Aldred (Kansas City, USA)

Real-World Deep Brain Stimulation Outcomes Using DBS Systems with Directionality and Multiple Independent Current Control

T. Zesiewicz, M. Barbe, S. Paschen, C. Luca, C. Zhao, F. Ponce, J. Durphy, J. Ostrem, N. Tomycz, T. Prell, M. Siddiqui, L. Chen, R. Jain (Tampa, USA)

Real-World Outcomes Using a Novel Directional Lead from a Multicenter DBS Registry for Parkinson’s Disease

G. Deuschl, R. Jain, J. Wang, M. Barbe, S. Paschen, C. Sik Lee, J. Volkmann, A. Kühn, J. Vesper (Kiel, Germany)

Relationship of satisfaction and adherence in remote digital monitoring: Updated results from a clinical drug trial in early Parkinson’s disease

B. Fehlmann, A. Thomann, W. Popp, F. Lipsmeier, E. Volkova-Volkmar, J. Friess, H. Svoboda, G. Pagano, T. Kilchemann, A. Bamdadian, W. Zago, R. Postuma, M. Lindemann, K. Taylor (Basel, Switzerland)

Remote identification of early, sensor-based markers of Parkinson’s Disease using participants’ smartphones: The Parkinson Progression Marker Initiative Digital sub-study

W. Popp, K. Taylor, T. Perumal, C. Tanner, A. Siderowf, L. Chahine, E. Brown, T. Simuni, T. Foroud, T. Kustermann, G. Pagano, H. Svoboda, M. Lindemann, K. Marek (Basel, Switzerland)

Remote physical activity monitoring programs for Veterans with Parkinson’s disease

K. Waddell, M. Patel, J. Wilkinson, S. Koganti, S. Wood, J. Morley (Philadelphia, USA)

Safety and Tolerability of Apomorphine Sublingual Film and Subcutaneous Apomorphine for the Treatment of OFF Episodes in Parkinson’s Disease

O. Rascol, W. Poewe, F. Stocchi, R. Chaudhuri, J. Kassubek, L. Lopez Manzanares, V. Leta, I. Zhang, A. Bowling, S. Wu, E. Pappert (Toulouse, France)

Safinamide as an adjunct to Levodopa Therapy in Asian and Caucasian Patients with Parkinson’s Disease and Motor Fluctuations: A post-hoc Analysis of the SETTLE study

R. Bhidayasiri, T. Ishida, RE. Husni, T. Kamei, I. Suzuki, SL. Wu, JW. Cho (Bangkok, Thailand)

Scaling the Roche Digital Health Technology Platform to Assess Disease Severity and Progression in Individuals with Parkinson’s Disease

W. Popp, K. Taylor, A. Bamdadian, L. Restelli, J. Schjodt-Eriksen, G. Pagano, H. Svoboda, A. Bonni, M. Lindemann (Basel, Switzerland)

Second Project: The feasibility and efficacy of virtual visits compared to in-person visits for management of Parkinson’s disease. A pilot, international, longitudinal, multicenter trial (NCT04695353).

A. García-Bustillo, O. Ojo, N. Okubadejo, JH. Ahn, J. Youn, E. Eldayem, A. Shalash, A. Cardozo, Z. Aldaajani, J. Bajwa, M. Spindler, M. Shackleford, Z. Mari, E. Cubo (Burgos, Spain)

Status Update of EPSILON: a Phase III, Randomised, Placebo-Controlled Study of Opicapone in Early Parkinson’s Disease

J. Ferreira, W. Poewe, O. Rascol, F. Stocchi, A. Antonini, J. Moreira, J-F. Rocha, P. Soares-da-Silva (Lisbon, Portugal)

Structural MRI prediction of freezing of gait in Parkinson’s disease after deep brain stimulation

T. Ollivier, R. Viard, A. Rolland, R. Lopes, L. Defebvre, G. Kuchcinski, D. Devos, C. Moreau (Lille, France)

Subcutaneous Foslevodopa/Foscarbidopa in Patients With Advanced Parkinson’s Disease: Results From a Randomized, Double-blind, Double-dummy Phase 3 Trial

M. Soileau, M. Spindler, J. Aldred, K. Budur, N. Fisseha, V. Fung, A. Jeong, T. Kimber, K. Klos, I. Litvan, D. O’Neill, W. Robieson, D. Standaert, S. Talapala, E. Okeanis Vaou, H. Zheng, M. Facheris, R. Hauser (Georgetown, USA)

Subgroup analyses by Unified Parkinson’s Disease Rating Scale Part III (UPDRS-III) of patients treated with levodopa inhalation powder 84mg or placebo to treat OFF symptoms in patients with Parkinson’s disease (PD)

D. Grosset, P. Zhao, R. Marini, R. Cohen, B. Blank (Glasgow, United Kingdom)

Systematic Literature Review of Key Outcomes Used to Assess Adjunctive Treatments for Parkinson’s Disease

A. Thach, M. Zichlin, M. Peddle, M. Du, A. Lerner, N. Kirson, A. Bowling, D. Mehta, R. Williams (Marlborough, USA)

The acceptability of wearable devices to measure mobility in people with Parkinson’s Disease: observations from Mobilise-D

A. Keogh, L. Alcock, P. Brown, M. Brozgol, E. Gazit, C. Hansen, J. Hausdorff, W. Maetzler, L. Rochester, A. Yarnall, B. Caulfield (Dublin, Ireland)

The anti-alpha-synuclein antibody Lu AF82422 was safe and well tolerated in a FIH-SAD study in healthy subjects and patients with PD

L. Buur, J. Wiedemann, F. Larsen, F. Ben Alaya-Fourati, P. Kallunki, D. Ditlevsen, M. Sørensen, D. Meulien (Valby, Denmark)

The countless visual features in PD and their impact on quality of life. A standardized diagnostic protocol

M. Meglio, E. Olivola, E. Palermo, G. Fioretto, D. D'Innocenzo, D. Centonze, N. Modugno (Pozzilli, Italy)

The REONPARK (REgistry of the use of COMT-inhibitors in the maNagement of patients with PARKinson’s disease in Spain who present early motor fluctuations) study: rationale and design of a national, multicentre and prospective study

L. Lopez-Manzanares, E. Casas-Peña, I. Muro-Garcia, I. Caballero, F. Almeida, I. Tegel, P. Sarasa (Madrid, Spain)

The STEPWISE Parkinson study: a Smartphone Based Exercise Solution for Patients With Parkinson’s Disease

S. Schootemeijer, N. de Vries, E. Macklin, A. Ascherio, M. Schwarzschild, B. Bloem (Nijmegen, Netherlands)

Time-to-event approach mitigates the treatment masking effect of symptomatics on MDS-UPDRS Part III

S. Zanigni, N. Shariati, T. Simuni, N. Pavese, K. Marek, R. Postuma, A. Monnet, E. Moore, A. Hahn, E. Davies, N. Pross, D. Trundell, T. Nikolcheva, G. Pagano (Basel, Switzerland)

Transauricular Vagus Nerve Stimulation (taVNS) for mild to moderate Parkinson’s Disease (PD)

V. Hinson, C. Mcleod, B. Badran, H. Boger, L. Lovera, A. Phan, J. Elm, T. Turner (Charleston, USA)

Treatment Selection in Multi-Arm Multi-Stage Clinical Trials in Parkinson Disease: The Search for the Ideal Neuroprotective Drug

C. Gonzalez-Robles, D. Byrom, R. Chapman, D. Dexter, S. Duty, R. Ellis-Doyle, E. Jabbari, G. Mills, H. Mortiboys, J. Rudiger, E. Sammler, P. Scurfield, S. Stott, G. Tofaris, L. Wei, A. Wong, ML. Zeissler, C. Carroll, T. Foltynie, O. Bandmann, A. Schapira (London, United Kingdom)

Validation of the PD Home Diary for Assessment of Motor Fluctuations in Advanced Parkinson’s Disease

M. Löhle, A. Bremer, F. Gandor, J. Timpka, P. Odin, G. Ebersbach, A. Storch (Rostock, Germany)

Vodobatinib, a potent, orally bioavailable brain-penetrating inhibitor of c-Abl as a potential neuroprotective agent for the treatment of Parkinson’s Disease

R. Walsh, S. Piccoli, O. Hurko, N. Damle, V. Ramanathan, S. Yao, D. Love, S. Mandhane, R. Talluri (Princeton, USA)